Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;9(5):686-691.
doi: 10.1016/j.jacep.2022.11.017. Epub 2023 Jan 18.

First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia

Tom De Potter  1 , Jippe C Balt  2 , Lucas Boersma  2 , Frederic Sacher  3 , Peter Neuzil  4 , Vivek Reddy  5 , Ilya Grigorov  6 , Atul Verma  7
Affiliations
Free article
Review

First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia

Tom De Potter et al. JACC Clin Electrophysiol. 2023 May.
Free article

Abstract

Ultra-low temperature cryoablation (ULTC) using near-critical nitrogen (-196ºC) has been shown to produce durable, contiguous, transmural lesions in ventricles of animal models. This report summarizes acute experience with ULTC in the first-ever 13 patients with recurrent monomorphic ventricular tachycardias (VTs) of both ischemic cardiomyopathy and nonischemic etiologies enrolled in the CryoCure-VT (Cryoablation for Monomorphic Ventricular Tachycardia; NCT04893317) clinical trial. After an average of 9.6 ± 4.6 endocardial ULTC lesions per patient, no clinical ventricular tachycardias were inducible in 91% of patients. Two procedure-related serious adverse events recorded in 2 patients resolved post-procedurally without clinical sequelae. Further investigation of both acute and chronic outcomes is warranted and ongoing.

Keywords: ultra-low temperature cryoablation; ventricular tachycardia ablation.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures All study expenses have been paid by Adagio Medical, Inc. Dr De Potter has received consulting fees and equity options from Adagio Medical, Inc. Drs Boersma and Verma have received consulting fees from Adagio Medical, Inc. Dr Grigorov is an employee of Adagio Medical, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

Associated data

LinkOut - more resources